Sonoma Pharmaceuticals Introduces Cost-Competitive Wound Care Technology; Shares Up 44%

Sonoma Pharmaceuticals (Nasdaq: SNOA) has introduced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Sonoma’s treatment solution, which uses the company’s Microcyn® Technology, is expected to be ready for commercial use in Europe in September 2023 and the US in 2024.

The company’s share price rose by 44% following the news.

Highlights

Sonoma’s Microcyn® Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing.

The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device for abdominal, laparoscopic, orthopedic, and periprosthetic procedures.

Sonoma’s product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions.

Sonoma’s pulse lavage container is also cost competitive with IV bags, the current standard of care.The company is accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, animal health care and non-toxic disinfectants. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, and oxygenates the cells in the area treated, assisting the body in its natural healing process.

Share This Article

 

About the Author

Sonoma Pharmaceuticals Introduces Cost-Competitive Wound Care Technology; Shares Up 44%

Editor Prism MarketView